OncologyPro
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
OncologyPro
Jun 29, 2024, 03:18 |
Blog
Peter Schmid's findings on atezolizumab and sacituzumab govitecan for advanced TNBC - ESMO
ESMO shared a post on LinkedIn: “For ESMO members: Breaking Science in Breast Cancer. Peter Schmid…
Jun 29, 2024, 02:57 |
Blog
Komal Jhaveri on antibody-drug conjugates in metastatic breast cancer - ESMO
ESMO shared a post on LinkedIn: “For European Society for Medical Oncology (ESMO) members: Breaking Science…
Jun 28, 2024, 11:43 |
Blog
Mafalda Oliveira discusses ESR1m ctDNA in MBC patients treated by camizestrant
The European Society for Medical Oncology (ESMO) posted on LinkedIn: “For ESMO members: Breaking Science…
Jun 28, 2024, 11:02 |
Blog
Severine Guiu explains triple combination therapy for ER+/HER2- ABC with HRR deficiency or MSI - The European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) posted on LinkedIn: . “For ESMO members:…
Jun 23, 2024, 10:53 |
Blog
Breaking Science in Breast Cancer with Hope Rugo - ESMO
ESMO shared a post on LinkedIn: "For ESMO members: Breaking Science in Breast Cancer. Hope Rugo…
Jun 23, 2024, 02:25 |
Blog
Elisa Agostinetto: Important data for patients who desire pregnancy after a diagnosis of breast cancer
Elisa Agostinetto shared a post by ESMO on X/Twitter: "Are assisted reproductive techniques safe in…
Jun 21, 2024, 14:02 |
Blog
Breaking Science in Breast Cancer with Matteo Lambertini - ESMO
ESMO shared on X/Twitter: "For ESMO members: Breaking Science in Breast Cancer. Matteo Lambertini discusses…
May 12, 2024, 12:13 |
Insight
Herbert Loong: 6 versus 3 years of adjuvant imatinib in high risk GISTs by Jean-Yves Blay et al.
Herbert Loong shared on LinkedIn: “Congrats Jean-Yves Blay and colleagues of French Sarcoma Group for completing…
All:
8
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube